Correction [0.03%]
改正措施
Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer [0.03%]
新一代ALK抑制剂洛拉替尼与克唑替尼一线治疗阳性非小细胞肺癌的疗效及成本效益分析
YuQi Shang,Hao Guo
YuQi Shang
Objectives: To assess the economic value of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer at medical insurance negotiation prices from the viewpoin...
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study [0.03%]
利用PHAMOUS研究将精神疾病患者的健康结果量表（HoNOS）和阳性与阴性症状量表（PANSS）映射到EQ-5D-3L中
Anne Kleijburg,Ben Wijnen,Wouter den Hollander et al.
Anne Kleijburg et al.
Objectives: When health outcomes relevant for economic evaluations are unavailable, algorithms can be developed to map utilities using available clinical outcome measures. This study aims to develop two mapping algorithms...
Correction [0.03%]
改正通知书
Content and cost of waste pharmaceuticals collected by pharmacies for disposal [0.03%]
药店收集待处置的废弃药物及其处理成本分析
Mehmet Akif Erişen,Mesut Ardıç
Mehmet Akif Erişen
Background: The research aims to the costs and contents of waste pharmaceuticals collected through pharmacies for disposal. This study adds significant value to the country's economy in terms of cost and number of medicin...
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc) [0.03%]
阿特珠单抗联合贝伐珠单抗和化疗治疗转移性、持续性或复发性宫颈癌的性价比分析（BEATcc研究）
Yixiao Zhu,Fenghao Shi,Huiting Lin et al.
Yixiao Zhu et al.
Background: The addition of atezolizumab to bevacizumab plus platinum regimen has demonstrated notable improvements in treating metastatic, persistent, or recurrent cervical cancer, but its cost-effectiveness requires fur...
Saco J de Visser,Adam F Cohen
Saco J de Visser
Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors in the treatment of chronic kidney disease: a systematic review [0.03%]
钠葡萄糖共转运蛋白2抑制剂治疗慢性肾脏病的成本效果系统评价
Anh Thi Ngoc Toan,Toi Lam Phung,Thao Thi Dang et al.
Anh Thi Ngoc Toan et al.
Introduction: Chronic kidney disease (CKD) is a severe, progressive condition with a significant economic burden. We performed a systematic review to assess the cost-effectiveness of sodium-glucose cotransporter 2 (SGLT2)...
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency [0.03%]
集中式HTA流程的医疗卫生系统中从审批到报销建议的时间。重点是波兰的HTA机构
Aneta Mela,Andrzej Tysarowski,Elżbieta Rdzanek et al.
Aneta Mela et al.
Background: To analyze the time from drug registration to reimbursement recommendations, we examined medicinal products, including new clinical indications, registered by the EMA between 2014 and 2019 across various thera...
A methodological guide for implementing and interpreting results of probabilistic analysis [0.03%]
概率分析实施和结果解读的方法指南
Xuanqian Xie,Alexis K Schaink,Olga Gajic-Veljanoski et al.
Xuanqian Xie et al.
Introduction: Probabilistic analysis, also referred to as probabilistic sensitivity analysis (PSA), is used extensively in cost-effectiveness evaluations of health technologies. We present methodological guidance for impl...